Effects of N6-methyladenosine modification on metabolic reprogramming in digestive tract tumors. 2024

Liang Yu, and Yuan Gao, and Qiongling Bao, and Min Xu, and Juan Lu, and Weibo Du
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.

N6-methyladenosine (m6A), the most abundant RNA modification within cells, participates in various biological and pathological processes, including self-renewal, invasion and proliferation, drug resistance, and stem cell characteristics. The m6A methylation plays a crucial role in tumors by regulating multiple RNA processes such as transcription, processing, and translation. Three protein types are primarily involved in m6A methylation: methyltransferases (such as METTL3, METTL14, ZC3H13, and KIAA1429), demethylases (such as FTO, ALKBH5), and RNA-binding proteins (such as the family of YTHDF, YTHDC1, YTHDC2, and IGF2BPs). Various metabolic pathways are reprogrammed in digestive tumors to meet the heightened growth demands and sustain cellular functionality. Recent studies have highlighted the extensive impact of m6A on the regulation of digestive tract tumor metabolism, further modulating tumor initiation and progression. Our review aims to provide a comprehensive understanding of the expression patterns, functional roles, and regulatory mechanisms of m6A in digestive tract tumor metabolism-related molecules and pathways. The characterization of expression profiles of m6A regulatory factors and in-depth studies on m6A methylation in digestive system tumors may provide new directions for clinical prediction and innovative therapeutic interventions.

UI MeSH Term Description Entries

Related Publications

Liang Yu, and Yuan Gao, and Qiongling Bao, and Min Xu, and Juan Lu, and Weibo Du
September 2022, Cancer letters,
Liang Yu, and Yuan Gao, and Qiongling Bao, and Min Xu, and Juan Lu, and Weibo Du
January 2021, Journal of oncology,
Liang Yu, and Yuan Gao, and Qiongling Bao, and Min Xu, and Juan Lu, and Weibo Du
October 2017, Current opinion in genetics & development,
Liang Yu, and Yuan Gao, and Qiongling Bao, and Min Xu, and Juan Lu, and Weibo Du
January 2023, Journal of oncology,
Liang Yu, and Yuan Gao, and Qiongling Bao, and Min Xu, and Juan Lu, and Weibo Du
February 2019, Cell research,
Liang Yu, and Yuan Gao, and Qiongling Bao, and Min Xu, and Juan Lu, and Weibo Du
April 2024, Oncology research and treatment,
Liang Yu, and Yuan Gao, and Qiongling Bao, and Min Xu, and Juan Lu, and Weibo Du
September 2020, Cancer gene therapy,
Liang Yu, and Yuan Gao, and Qiongling Bao, and Min Xu, and Juan Lu, and Weibo Du
August 2020, ACS chemical biology,
Liang Yu, and Yuan Gao, and Qiongling Bao, and Min Xu, and Juan Lu, and Weibo Du
April 2016, Yi chuan = Hereditas,
Liang Yu, and Yuan Gao, and Qiongling Bao, and Min Xu, and Juan Lu, and Weibo Du
November 2023, Reproductive sciences (Thousand Oaks, Calif.),
Copied contents to your clipboard!